Defragmenting the CGT Supply Chain

The advanced therapy supply chain consist of a complex web of stakeholders. Clinical sites, couriers, cryopreservation facilities, CDMOs, regulators, care teams… each node is critical, yet all too often they operate in isolation. Sponsors are stuck navigating a landscape where data systems don’t talk to each other, chain of custody runs into vulnerabilities at every handoff, and end-to-end visibility is limited. This creates a fragile ecosystem where even minor disruptions can quickly cascade into major consequences.

This whitepaper explores the critical need to defragment and integrate the supply chain for cell and gene therapies (CGT) and explores key topics, including:

• The hidden cost of siloed systems
• The value of end-to-end integration
• Regulatory evolution and the push for standardization

The therapies of tomorrow deserve supply chains that are built to deliver. Download the whitepaper and discover how Cryoport Systems is building that future, today.